Drugs /

oxaliplatin

Back to Drugs List

Overview

Generic Name(s):
oxaliplatin
Trade Name(s):
Eloxatin, Dacotin, Eloxatine, and Dacplat
NCI Definition [1]:
An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)

Clinical Trials

View Clinical Trials for oxaliplatin

Oxaliplatin has been investigated in 91 clinical trials, of which 78 are open and 13 are closed. Of the trials investigating oxaliplatin, 2 are early phase 1 (2 open), 13 are phase 1 (10 open), 14 are phase 1/phase 2 (9 open), 37 are phase 2 (33 open), 2 are phase 2/phase 3 (2 open), and 23 are phase 3 (22 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for oxaliplatin clinical trials.

Adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and colorectal adenocarcinoma are the most common diseases being investigated in oxaliplatin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Oxaliplatin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Oxaliplatin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating oxaliplatin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Eloxatin, Dacotin, sanofi synthelabo brand of oxaliplatin, 266046, oxaliplatin (substance), oxalatoplatinum, oxalatoplatin, sr-96669, platinum(ii)-1,2-cyclohexanediamine oxalate, [sp-4-2-(1r-trans)]-(1,2,cyclohexanediamine-n,n')[ethanedioato(2--)-o,o']platinum, dacplat, oxalato-(1,2-cyclohexanediamine)platinum ii, diaminocyclohexane oxalatoplatinum, sanofi brand of oxaliplatin, oxalato (trans-l-1,2-diaminocyclohexane)platinum(ii), oxalato (1r,2r-cyclohexanediamine)platinum(ii), 1,2-diamminocyclohexane(trans-1)oxolatoplatinum(ii), trans-l diaminocyclohexane oxalatoplatinum, 63121-00-6, diaminocyclohexane oxalatoplatinum, l-ohp cpd, [(1r,-2r)-1,2-cyclohexanediamine-n,n'][oxalato (2--)-o,o']platinum, Eloxatine, Dacplat, oxaliplatin (product), jm-83, eloxatin, oxaliplatin [chemical/ingredient], oxaliplatinum, 1,2-diaminocyclohexane platinum oxalate, ai heng, trans-l dach oxalatoplatinum, oxalatoplatinum, oxaliplatin, oxaliplatine, 57004, rp-54780, oxaliplatino, oxalatoplatin, aiheng, l-ohp, rp 54780, oxaliplatin, (sp-4-2-(1r-trans))-isomer, oxaliplatin, 1-ohp
Drug Categories [2]:
Alkylating agents
NCIT ID [1]:
C1181
SNOMED ID [1]:
C-15316

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.